Cardiovascular risk markers beyond cholesterol

Why a lipid panel alone is not enough

The classic lipid panel answers the question 'how many atherogenic particles are in the blood' but not 'how active is the process in the vessel wall'. Two people with identical LDL stand in different positions if one has smouldering vascular inflammation and the other does not. Non-lipid risk markers exist precisely for this second layer of assessment.

Dyslipidemia guidelines weigh the whole profile: age, blood pressure, smoking, diabetes and family history. Laboratory markers of inflammation and thrombosis do not replace that assessment; they refine it in borderline cases, when the formal scales place risk in the middle.

Homocysteine: a metabolic marker of vascular risk

Homocysteine is an intermediate product of methionine metabolism. Its excess damages the inner lining of vessels, so a persistently elevated level is treated as an independent vascular risk factor. Most often the level rises with deficiency of vitamins B12, B6 and folate — the cofactors of the reactions that clear it.

The second common cause of elevation is declining kidney function: homocysteine is cleared renally, and its rise parallels creatinine. A report with high homocysteine is always read together with creatinine, vitamin B12 and folate — only then is it clear which link has failed.

CRP and interleukin-6: the inflammatory background

C-reactive protein is the classic inflammation marker, produced by the liver in response to signals from inflammatory cells. For vascular assessment the high-sensitivity version is used: it detects not acute inflammation but the low chronic background that feeds plaque growth for years. A fresh cold or any flared focus on the day of testing makes the result unusable for risk estimation — it is revisited after recovery.

Interleukin-6 is the signalling molecule that sits above CRP in the inflammatory cascade: it is what orders the liver to synthesize CRP and fibrinogen. In studies, persistently elevated interleukin-6 in healthy people is linked to higher vascular risk; clinically it is read as part of an inflammatory panel, not as a stand-alone test.

Fibrinogen and D-dimer: the thrombotic layer

Fibrinogen is a clotting protein and simultaneously an acute-phase protein: inflammation raises it, and its excess makes blood more prone to forming clots. High fibrinogen together with high CRP is the typical signature of a systemic inflammatory response.

D-dimer is a breakdown product of an already formed clot. Its main clinical role is excluding fresh thrombosis when probability is low, not assessing long-term risk. In a preventive panel D-dimer is auxiliary: it answers 'is there active clotting now', while fibrinogen answers 'how large is the potential for clot formation'.

Assembling the markers into one picture

The reading order is layered. First layer — lipids: LDL, apolipoprotein B, triglycerides. Second — inflammatory background: high-sensitivity CRP, with interleukin-6 if needed. Third — metabolic and thrombotic: homocysteine, fibrinogen, and D-dimer when fresh thrombosis is suspected. Each layer answers its own question, and the conclusion comes from the combination, not from the worst single number.

The key interpretive rule: inflammatory markers are drawn outside acute illness, and homocysteine is drawn together with the vitamins it depends on. Interpreting such a set is the clinician's task: weighing the numbers against age, pressure, weight and family history to tell cause from consequence.

When extra risk markers make sense

Markers covered in this article

Frequently asked questions

Sources

Keep reading